Literature DB >> 31010583

The value of quantitative CT texture analysis in differentiation of angiomyolipoma without visible fat from clear cell renal cell carcinoma on four-phase contrast-enhanced CT images.

M-W You1, N Kim2, H J Choi3.   

Abstract

AIM: To investigate the diagnostic performance and usefulness of texture analysis in differentiating angiomyolipoma (AML) without visible fat from clear cell renal cell carcinoma (ccRCC) on four-phase contrast-enhanced computed tomography (CECT).
MATERIALS AND METHODS: Seventeen patients with AML without visible fat and 50 patients with ccRCC of size ≤4.5 cm who had also undergone preoperative four-phase CECT were included in this study. The histogram, grey-level co-occurrence matrix (GLCM), and grey-level run length matrix (GLRLM) were evaluated. Sequential feature selection (SFS) and support vector machine (SVM) classifier with leave-one-out cross validation were used.
RESULTS: Using the SFS and SVM classifiers, five texture features were selected; mean (unenhanced), standard deviation (unenhanced and excretory), cluster prominence (nephrographic), and long-run high grey-level emphasis (corticomedullary). Diagnostic performance of the five selected texture features for all CT phases was as follows: 82% sensitivity, 76% specificity, 85% accuracy, and 85 area under the receiver operating characteristic curve (AUC). In the subgroup analysis, the AUCs of each phase were significantly >0.5 (p<0.05). In the pairwise comparison of AUCs between four phases, there were no significant differences between the four phases except the unenhanced and corticomedullary phases (p=0.015), i.e., the unenhanced phase showed slightly higher AUC than the corticomedullary phase.
CONCLUSIONS: Texture analysis of small renal masses (≤4.5 cm) on four-phase CECT can accurately differentiate AML without visible fat from ccRCC and showed good diagnostic performance for both the unenhanced and enhanced phases.
Copyright © 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31010583     DOI: 10.1016/j.crad.2019.02.018

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  MR texture analysis in differentiating renal cell carcinoma from lipid-poor angiomyolipoma and oncocytoma.

Authors:  Abdul Razik; Ankur Goyal; Raju Sharma; Devasenathipathy Kandasamy; Amlesh Seth; Prasenjit Das; Balaji Ganeshan
Journal:  Br J Radiol       Date:  2020-08-26       Impact factor: 3.039

2.  A Non-Invasive Scoring System to Differential Diagnosis of Clear Cell Renal Cell Carcinoma (ccRCC) From Renal Angiomyolipoma Without Visible Fat (RAML-wvf) Based on CT Features.

Authors:  Xiao-Jie Wang; Bai-Qiang Qu; Jia-Ping Zhou; Qiao-Mei Zhou; Yuan-Fei Lu; Yao Pan; Jian-Xia Xu; You-You Miu; Hong-Qing Wang; Ri-Sheng Yu
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

3.  Prediction of the World Health Organization Grade of rectal neuroendocrine tumors based on CT histogram analysis.

Authors:  Ping Liang; Chuou Xu; Fangqin Tan; Shichao Li; Mingzhen Chen; Daoyu Hu; Ihab Kamel; Yaqi Duan; Zhen Li
Journal:  Cancer Med       Date:  2020-12-01       Impact factor: 4.452

4.  Review of Value of CT Texture Analysis and Machine Learning in Differentiating Fat-Poor Renal Angiomyolipoma from Renal Cell Carcinoma.

Authors:  Yuhan Zhang; Xu Li; Yang Lv; Xinquan Gu
Journal:  Tomography       Date:  2020-12

5.  The Prognostic Value of Radiomics Features Extracted From Computed Tomography in Patients With Localized Clear Cell Renal Cell Carcinoma After Nephrectomy.

Authors:  Xin Tang; Tong Pang; Wei-Feng Yan; Wen-Lei Qian; You-Ling Gong; Zhi-Gang Yang
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

6.  Histogram analysis with computed tomography angiography for discriminating soft tissue sarcoma from benign soft tissue tumor.

Authors:  Gang Wu; Ruyi Xie; Yitong Li; Bowen Hou; John N Morelli; Xiaoming Li
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.